|
|
Vol. 26.00 – 13 January, 2025
|
|
|
|
|
|
|
|
The authors analyzed the DESCAR-T registry database, encompassing all pediatric and adult patients with hematologic malignancies who received CAR T cell therapy in France since 1 July 2018. [Nature Medicine]
|
|
|
|
|
|
PUBLICATIONSListed by the impact factor of the journal
|
|
|
|
|
|
Scientists evaluated the efficacy of autologous monocyte-derived macrophage therapy compared to standard medical care in adult patients with compensated cirrhosis and Model for End-Stage Liver Disease.
[Nature Medicine]
|
|
|
|
|
|
Investigators demonstrated that human STELLA was inadequate, while mouse STELLA was fully proficient in inhibiting the abnormal DNA methylation and oncogenic functions of ubiquitin-like with plant homeodomain and RING finger domains 1 (UHRF1) in human cancer cells.
[Nature Communications]
|
|
|
|
|
|
The authors showed CRISPR-Cas13d variant CasRx effectively reduced overexpressed C9orf72 sense and antisense repeat transcripts and dipeptide repeat proteins in HEK cells.
[Nature Communications]
|
|
|
|
|
|
A first-in-human clinical study of a corneal endothelial cell substitute derived from a clinical-grade iPSC line showed improvement of visual acuity and corneal stromal edema, with no adverse events for up to one year after surgery for the treatment of bullous keratopathy.
[Cell Reports Medicine]
|
|
|
|
|
|
Scientists reported the utilization of tEGFR-expressing claudin18.2-targeted CAR-T cells to treat three patients with advanced pancreatic cancer.
[Molecular Therapy]
|
|
|
|
|
|
Researchers modified carcinoembryonic antigen (CEA)-specific CAR-T cells, aiming to stimulate endogenous CD8+ T cell responses against neoantigens that were derived from CEA-positive tumors destroyed by the CAR T cells.
[Journal For Immunotherapy of Cancer]
|
|
|
|
|
|
The authors gene-edited a cGMP compliant human induced pluripotent stem cell (hiPSC) line at the AAVS1 safe harbor locus enabling constitutive expression of a human sodium iodide symporter-monomeric(m)GFP fusion reporter in hiPSCs and their differentiated progeny. [Molecular Therapy-Methods & Clinical Development]
|
|
|
|
|
|
Researchers chose the novel nucleic acid linked immuno-sandwich assay, to investigate a predefined panel of neuroinflammatory markers in plasma samples collected from spinal muscular atrophy patients at baseline and six months after Zolgensma® treatment. [Gene Therapy]
|
|
|
|
|
|
|
|
Investigators discuss recent approaches to clinically target tumor myeloid cells, focusing on reprogramming myeloid cells to promote antitumor immunity. [Trends in Cancer]
|
|
|
|
|
|
|
|
Base editing, antisense oligonucleotides, and siRNA therapies that target low-density lipoprotein and the genes encoding molecules that regulate it are being tested in several clinical trials.
[Nature Medicine]
|
|
|
|
|
|
Bayer AG and BlueRock Therapeutics LP announced plans to initiate a Phase III clinical trial for bemdaneprocel, its investigational cell therapy for Parkinson’s disease. [BlueRock Therapeutics]
|
|
|
|
|
|
|
|
February 1-4, 2025 San Diego, California, United States
|
|
|
|
|
|
|
|
|
|
|
Biogen – Cambridge, Massachusetts, United States
|
|
|
|
|
|
|
University of California San Francisco – San Francisco, California, United States
|
|
|
|
|
|
|
Biogen – San Francisco, California, United States
|
|
|
|
|
|
|
IFOM ETS – The AIRC Institute of Molecular Oncology – Milan, Italy
|
|
|
|
|
|
|
The University of Pennsylvania – Philadelphia, Pennsylvania, United States
|
|
|
|
|
|